The VADEX technology platform is a self-adjuvanting protein nanoparticle platform. Its constituent units are formed by fusing a specific-sequence amphiphilic peptide with a superfolder green fluorescent protein. Although this amphiphilic peptide is only 19 amino acids long, it possesses both adjuvant functionality and nanoparticle self-assembly capability. Foreign proteins can be directly fused onto the nanoparticles or linked to the nanoparticles through irreversible complementary conjugation. Because nanoparticles formed using VADEX technology can induce long-lasting antibody responses without the need for external adjuvants, vaccines developed based on VADEX technology can withstand high temperatures of up to 40°C for more than two months. With this technology, children around the world, whether living in deserts or tropical rainforests, will be able to grow up healthy in the future.
(The content above was translated by AI.)

1. T-1101: Global first-in-class Hec1/Nek2 targeted small molecule inhibitor
2. T-1201: Novel targeted small molecule-SN-38 conjugate anticancer drug
3. T-1301: Multi-targeted tyrosine kinase inhibitor
4. T-1501: Novel small molecule-DM-1 conjugate targeted anticancer drug
(The content above was translated by AI.)

1. EF-001 (Cerebraca® Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and